Indication
As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
Medicine details
- Medicine name:
- acalabrutinib (Calquence)
- SMC ID:
- SMC2347
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 14 June 2021
- SMC meeting date:
- 04 May 2021
- Patient group submission deadline:
- 05 April 2021